title: Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.
abstract: OBJECTIVE
  To evaluate the role of the inflammatory biomarkers C-reactive protein (CRP), myeloperoxidase, paraoxonase, secretory phospholipase A2 group IIA (sPLA2), lipoprotein-associated phospholipase A2, fibrinogen, macrophage chemoattractant protein-1 and adiponectin, in predicting the risk of coronary heart disease (CHD) among people estimated to be at intermediate risk according to the Framingham Risk Score (FRS).
  
  
  METHODS
  Prospective case-control study nested in EPIC-Norfolk cohort.
  
  
  METHODS
  Norfolk, UK.
  
  
  METHODS
  Apparently healthy men and women aged 45-79 years.
  
  
  METHODS
  Risk of future coronary artery disease.
  
  
  RESULTS
  For participants predicted to be at intermediate risk by the FRS, the highest c statistics were observed for FRS plus CRP (0.61, 95% CI 0.57 to 0.65) and for FRS plus sPLA2 (0.56, 95% CI 0.52 to 0.6). Net correct reclassification of cases and controls for each marker was assessed for people across the entire risk spectrum and again for people at intermediate risk only. The largest differences were observed for CRP, 12.0% net reclassification improvement in the entire risk spectrum and 28.4% net reclassification improvement in the intermediate-risk group and for sPLA2, the net reclassification improvement was 6.4% in the entire risk spectrum and 16.3% in the intermediate-risk group.
  
  
  CONCLUSIONS
  The discriminatory potential of inflammatory biomarkers was substantially different when analysed across the entire risk spectrum compared with the subgroup of people at intermediate risk.
authors: Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
authors: J S
authors: JS
authors: Rana
authors: M
authors: M
authors: Cote
authors: J-P
authors: JP
authors: Després
authors: M S
authors: MS
authors: Sandhu
authors: P J
authors: PJ
authors: Talmud
authors: E
authors: E
authors: Ninio
authors: N J
authors: NJ
authors: Wareham
authors: J J P
authors: JJ
authors: Kastelein
authors: A H
authors: AH
authors: Zwinderman
authors: K-T
authors: KT
authors: Khaw
authors: S M
authors: SM
authors: Boekholdt
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D052242:Adiponectin / Q000097:blood; D000368:Aged; D043303:Aryldialkylphosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D002630:Chemotactic Factors / Q000097:blood; D003324:Coronary Artery Disease / Q000175:diagnosis*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D054501:Group II Phospholipases A2 / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000097:blood; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000097:blood; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D052242:Adiponectin; D015415:Biomarkers; D002630:Chemotactic Factors; D005340:Fibrinogen; D002097:C-Reactive Protein; D009195:Peroxidase; D054501:Group II Phospholipases A2; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D043303:Aryldialkylphosphatase